Mpox Is Back in the News. Here’s What Clinicians Need to Know.
This new surge is different, WHO leader says
Related Articles
New National Strategy for Suicide Prevention Reflects Today’s Challenges
In April, the U.S. Department of Health and Human Services released its 2024 National Strategy for Suicide Prevention. The comprehensive plan comes as suicide deaths…
Journal Editors Sound Alarm on Predatory Medical Journals
These journals take advantage of the current academic environment with its pressure to publish
Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Prostate cancer, advanced prostate cancer, novel targets for mHSPC, Metastatic Hormone Sensitive Prostate Cancer (mHSPC), TITAN study, ENZAMET trial, ARCHES trial, CHAARTED trial, Prognostication in…
NIH issues a policy to widen access to medical products that emerge from government-funded research
NIH policy asks companies seeking licenses to sell medical products invented with government research to submit plans for ensuring greater access to patients.
Spotify’s share surge arrives at AI crossroads
Daniel Ek is cranking up the volume at Spotify Technology . Two years ago, the U.S.-listed music streamer faced heat from activist investor ValueAct Capital…
Solutions for a Livable Earth | Hopkins Bloomberg Public Health Magazine
From innovating ways to preserve glacial ice to predicting climate-driven migration shifts to building resilient cities, researchers are exploring scalable solutions to safeguard a planet…
Scribe
Welcome to Scribe, your new assistant for clinical note-taking! This HIPAA compliant AI-powered tool listens to your patient visits and creates an EHR-ready summary. Say…
FTC slams PBMs for boosting specialty drug prices at the expense of the U.S. health care system
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
Novel Treatment Targets in the Metastatic Castrate-Resistant Prostate Cancer Disease Space
prostate cancer, metastatic castration resistant prostate cancer (mCRPC), Metastatic Castrate-Resistant Prostate Cancer Disease Space, EPI-7386, EPI-7386 plus Enzalutamide, Enzalutamide, RNAseq, CYPIDES trial, Oral bavdegalutamide (ARV-110),…